KRRO NASDAQ
Korro Bio, Inc.
1W: -18.4%
1M: -35.9%
3M: -18.6%
YTD: +13.7%
1Y: -39.4%
3Y: -50.7%
5Y: -98.2%
$9.15
-0.82 (-8.22%)
Pre-Market: $9.78 (+0.62, +6.83%)
Weekly Expected Move ±8.7%
$8
$9
$10
$11
$12
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$20.7M
Congress—
ETF Holdings—
Key Statistics
Market Cap$91.1M
52W Range5.204-55.89
Volume167,716
Avg Volume176,937
Beta2.23
Dividend—
Analyst Ratings
Company Info
CEORam Aiyar
Employees112
SectorHealthcare
IndustryBiotechnology
IPO Date2019-10-03
Websitekorrobio.com
One Kendall Square
Cambridge, MA 02139-1562
US
Cambridge, MA 02139-1562
US
781-315-4600
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Latest News
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Korro to Participate in Upcoming Investor Conferences
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lynx1 Capital Manage | P-Purchase | 520 | $10.60 | 2026-03-31 |
| Lynx1 Capital Manage | 0 | — | 2026-03-31 | |
| Yang Rick | P-Purchase | 207,100 | $11.11 | 2026-03-10 |
| SANDELL SCOTT D | P-Purchase | 207,100 | $11.11 | 2026-03-10 |
| New Enterprise Assoc | P-Purchase | 207,100 | $11.11 | 2026-03-10 |